Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan

In conclusion, nivolumab showed a similar safety profile and comparable effectiveness to that reported in clinical trials for relapsed/refractory cHL (CheckMate 205, ONO-4538-15).PMID:38521840 | DOI:10.1007/s12185-024-03734-y

Source: International Journal of Hematology - March 24, 2024 Category: Hematology Authors: Akira Kawasaki Kiyohiko Hatake Itaru Matsumura Koji Izutsu Tomohiro Hoshino Ayumi Akamatsu Akito Kakuuchi Kensei Tobinai Source Type: research